Christopher Haig, Efemoral Medical, Inc. - Co-Founder and CEO of PAD Treatment Tech | LSI USA '25

About this Video

• Video Title: Christopher Haig, Efemoral Medical, Inc. - Co-Founder and CEO of PAD Treatment Tech | LSI USA '25
• Channel: LSI - Life Science Intelligence™
• Speakers: Christopher Haig
• Duration: 00:09:25

Introduction

This video features Christopher Haig, CEO and co-founder of Ephemeral Medical, presenting at LSI USA '25. He discusses Ephemeral Medical's bioresorbable scaffold designed to treat peripheral arterial disease (PAD), highlighting its potential to improve upon existing treatment limitations and offering a more durable solution.

Key Takeaways

• PAD is a significant global health issue: Affecting millions worldwide, including a substantial number of Americans, PAD places an enormous economic burden on healthcare systems. Current treatments often have poor long-term outcomes, leading to re-interventions or even amputation.
• Ephemeral Medical's bioresorbable scaffold offers a novel solution: The device is designed with enhanced radial strength and flexibility, addressing the shortcomings of existing self-expanding stents. Its bioresorbable nature and proprietary coating contribute to its durability and safety.
• Clinical trials show promising results: Early clinical trial data demonstrates successful treatment of PAD, with a high rate of complete lesion restoration and improved patient outcomes. Long-term data will be presented at a future conference.
• Strong team and financial backing: Ephemeral Medical boasts a team with extensive experience in cardiovascular medical devices and a successful fundraising history, indicating strong potential for future growth and development.
• Market Opportunity: The existing market for PAD treatment is large and underserved, representing a significant growth opportunity for a device that provides durable and effective treatment.